Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Breast Cancer Research

Fig. 4

From: Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells

Fig. 4

a MDAMB231 cells treated with DMSO or 250 nM prexasertib and/or 25 μM olaparib for 24 h were analyzed for BRCA1 foci using immunofluorescence. b More than 75 cells from three independent experiments were analyzed for percentage of cells that shows > 5 BRCA1 foci and represented as histogram with standard error. c MDAMB231 cells treated with DMSO or 250 nM prexasertib and/or 25 μM olaparib for 24 h were analyzed for RAD51 foci using immunofluorescence. d More than 75 cells from three independent experiments were analyzed for percentage of cells that shows > 5 RAD51 foci and represented as histogram with standard error. e MDAMB231 cells treated with DMSO or 250 nM prexasertib and/or 25 μM olaparib for 24 h were analyzed for γH2AX foci using immunofluorescence. f More than 75 cells from three independent experiments were analyzed for percentage of cells that shows > 7 γH2AX foci and represented as histogram with standard error. Scale bar represents 5 μM (**p < 0.01, ***p < 0.001, and ****p < 0.0001)

Back to article page